公开(公告)号：US20250057952A1

公开(公告)日：2025-02-20

申请号：US18562603

申请日：2022-05-23

Applicant: CELLECTIS S.A.

Inventor： Shipra DAS ,  Julien VALTON ,  Laurent POIROT ,  Philippe DUCHATEAU

IPC: A61K39/00 ,  A61K39/395 ,  A61P35/00 ,  C12N15/90

Abstract: The invention relates to methods of treatment of a solid tumor in a patient in need thereof, comprising administering to the patient: (i) an effective amount of engineered immune cells originating from a donor expressing at their cell surface a Chimeric Antigen Receptor (CAR) directed against Fibroblast Activation Protein (FAP), and (ii) an effective amount of an immunotherapy treatment that elicits an immune response in the patient.

公开(公告)号：US20230248825A1

公开(公告)日：2023-08-10

申请号：US18005284

申请日：2021-07-23

Applicant: CELLECTIS S.A.

Inventor： Shipra DAS ,  Sumin JO ,  Alexandre JUILLERAT ,  Julien VALTON ,  Laurent POIROT ,  Philippe DUCHATEAU

IPC: A61K39/00 ,  C12N9/22 ,  C12N15/11 ,  C12N15/90 ,  C12N5/0783 ,  C12N15/113 ,  A61K39/395 ,  A61P35/00

CPC classification number: A61K39/4633 ,  C12N9/22 ,  C12N15/11 ,  C12N15/907 ,  C12N5/0636 ,  A61K39/4611 ,  A61K39/4643 ,  C12N15/1138 ,  A61K39/3955 ,  A61K39/4631 ,  A61P35/00 ,  C12N2800/80 ,  C12N2310/20 ,  C12N2506/11 ,  C12N2501/515 ,  C12N2501/51 ,  C12N2501/2302 ,  A61K2039/5158 ,  C12N2310/531 ,  C12N2310/14

Abstract: The invention relates to therapeutic compositions for allogeneic cellular therapy comprising TCR deficient T-cells, which are genetically engineered to express immune cell engagers, and methods related thereto.